CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Diverse patient population helps identify gene variant associated with childhood asthmaon February 26, 2021 at 11:50 pm
Researchers at Henry Ford Health System, as part of a national asthma collaborative, have identified a gene variant associated with childhood asthma that underscores the importance of including ...
- Gene Editing’s Vast, Double-Edged Potentialon February 26, 2021 at 12:51 pm
CRISPR technology should be limited exclusively to healing genetic diseases in breathing humans.
- DNA Origami Used to Monitor CRISPR Gene Targetingon February 26, 2021 at 11:38 am
CRISPR gene editing has transformed research, but it is not perfect, and can sometimes target unintended genes. To watch CRISPR enzymes respond to different genes, Leipzig University researchers devel ...
- Hotter, drier, CRISPR: Editing for climate changeon February 26, 2021 at 6:05 am
Gene editing technology will play a vital role in climate-proofing future crops to protect global food supplies, according to scientists at The University of Queensland.
- What you need to know about gene editing in agricultureon February 25, 2021 at 6:32 am
Are there trade implications if the UK starts growing gene edited crops and the EU doesn't? Why does the NFU support gene editing? All these questions and more are answered below by NFU specialists ...
- New Gene-editing Tool Discoveredon February 24, 2021 at 4:08 am
A new gene-editing technique that allows for the programming of sequential cuts -- or edits -- over time has been discovered by University of Illinois Chicago researchers. CRISPR uses an enzyme called ...
- CRISPR Therapeutics creates gene-based medicineson February 23, 2021 at 4:00 pm
Gene-Editing Genius CRISPR (clustered regularly interspaced short palindromic repeats) has been making news about research and investment. Scientists learned that CRISPR, a naturally occurring ...
- New gene-editing tool enables programming of sequential cuts over timeon February 23, 2021 at 3:29 pm
Researchers from the University of Illinois Chicago have discovered a new gene-editing technique that allows for the programming of sequential cuts -- or edits -- over time.
- Researchers invent new gene-editing toolon February 23, 2021 at 10:12 am
Researchers from the University of Illinois Chicago have discovered a new gene-editing technique that allows for the programming of sequential cuts—or edits—over time.
- After the Nobel, what next for Crispr gene-editing therapies?on February 21, 2021 at 1:13 am
Hailed as the ‘molecular scissors’ that will allow us to rewrite our genes, the DNA tool is being trialled in treatments for everything from sickle-cell anaemia to cancer ...
via Bing News